Table 2 Relationship between HBXIP protein overexpression and the clinicopathological features of ovarian cancer
From: HBXIP overexpression is correlated with the clinical features and survival outcome of ovarian cancer
Variables | No. of case (n) | HBXIP strong positive rate (%) | χ2 | P value |
|---|---|---|---|---|
Age (years) | ||||
≥ 55 | 65 | 36 (55.4%) | 1.259 | 0.262 |
< 55 | 55 | 36 (65.5%) | ||
Tumor size | ||||
≤ 5 cm | 59 | 37 (62.7%) | 0.356 | 0.551 |
> 5 cm | 61 | 35 (57.4%) | ||
M classification | ||||
M0 | 77 | 46 (59.7%) | 0.006 | 0.938 |
M1 | 43 | 26 (60.5%) | ||
Lymph node status | ||||
N0 | 60 | 30 (50.0%) | 5.000 | 0.025* |
N+ | 60 | 42 (70.0%) | ||
Histological grade | ||||
Grade-1 | 41 | 19 (46.3%) | 6.629 | 0.036* |
Grade-2 | 28 | 16 (57.1%) | ||
Grade-3 | 51 | 37 (72.5%) | ||
Clinical stage | ||||
I + II | 39 | 16 (41.0%) | 8.667 | 0.003** |
III + IV | 81 | 56 (69.1%) | ||